by Plus Therapeutics | Jul 21, 2025 | Uncategorized
Central nervous system (CNS) cancers—including aggressive diseases like glioblastoma (GBM) and leptomeningeal metastases (LM)—remain among the most challenging cancers to treat. Despite decades of research, treatment options remain limited, and very few therapies have...
by Plus Therapeutics | Jun 30, 2025 | Uncategorized
Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care At Plus Therapeutics, our mission is clear: to address some of the toughest challenges in oncology by improving the efficacy, precision, and convenience of modern radiotherapeutic treatments....
by Plus Therapeutics | Jun 12, 2025 | Uncategorized
At Plus Therapeutics, our mission is rooted in innovation, precision, and the pursuit of better outcomes for patients facing some of the most aggressive and difficult-to-treat cancers. In a recent interview with AlphaStreet, our President and CEO, Marc Hedrick, M.D.,...
by Plus Therapeutics | May 15, 2025 | Uncategorized
Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast In case you missed it, Plus Therapeutics President and CEO Dr. Marc Hedrick recently joined Ayesha Rashid on the Xtalks Life Sciences Podcast to discuss the company’s...
by Plus Therapeutics | May 1, 2025 | GBM, LM, PBC, Uncategorized
Honoring Brain Cancer Awareness Month: Advancing Research, Raising Voices, and Recruiting for Clinical Trials May is Brain Cancer Awareness Month! A time dedicated to elevating the voices of patients, caregivers, and advocates affected by brain tumors. At Plus...
by Plus Therapeutics | Apr 12, 2025 | GBM, LM, PBC, Uncategorized
Advancing Radiotherapeutic Solutions for Rare Cancers At Plus Therapeutics, our mission is clear: to develop safe, effective, and lasting solutions for patients facing rare and hard-to-treat cancers. Every day, our dedicated team works alongside clinicians and...
Recent Comments